Skip to main content
SpringerLink
Log in

Antidepressivakombinationen

  • Chapter
Akute und therapieresistente Depressionen

  • 4834 Accesses

Zusammenfassung

Eine Indikation für Kombinationen von Antidepressiva bei therapieresistenten depressiven Patienten besteht erst bei Nichtansprechen auf eine hinsichtlich Dosis und Dauer ausreichend durchgeführte Antidepressivamonotherapie und bei Vorliegen von medizinischen und persönlichen Gründen gegen den Einsatz gängiger Standardverfahren wie z. B. Lithiumaugmentation. Klinisch sinnvoll sind Kombinationen von Antidepressiva mit unterschiedlichem Wirkprofil, so z. B. das Hinzufügen eines selektiven Serotonin-Wiederaufnahmehemmers zu einem trizyklischem Antidepressivum wie Amitriptylin. Bei der Kombination von Antidepressiva muss das erhöhte Nebenwirkungsrisiko durch die Addition von gleichartigen unerwünschten Wirkungen sowie mögliche Plasmaspiegelerhöhungen bei gleichen hepatischen Metabolisierungswegen beachtet werden. Regelmäßige Plasmaspiegelkontrollen und ggf. eine Dosisreduktion sollten hierbei durchgeführt werden. Um den zukünftigen Stellenwert der neu zugelassenen, mehr selektiv wirksamen Antidepressiva bei der Kombinationsbehandlung besser einschätzen zu können, sind weitere kontrollierte Untersuchungen wünschenswert.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Amsterdam JD, Garcia-Espana F, Rosenzweig M (1997) Clomipramine augmentation in treatment-resistant depression. Depress Anxiety 5: 84–90

    Article  PubMed  Google Scholar 

  • Appelberg BG, Syvalahti EK, Koskinen TE, Mehtonen OP, Muhonen TT, Naukkarinen HH (2001) Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a Placebo-controlled, randomized, double-blind, Placebo wash-in study. J Clin Psychiatry 62: 448–452

    PubMed  Google Scholar 

  • Benazzi F (1999) Venlafaxine-fluoxetine interaction. J Clin Psychopharmacol 19: 96–98

    Article  PubMed  Google Scholar 

  • Berlanga C, Ortega-Soto HA (1995) A 3-year follow-up of a group of treatment-resistant depressed patients with a MAOI/tricyclic combination. J Affect Disord 34: 187–192

    Article  PubMed  Google Scholar 

  • Bhatara VS, Magnus RD, Paul KL (1998) Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms. Ann Pharmacotherapy 32: 432–436

    Article  Google Scholar 

  • Bodkin JA, Lasser RA, Wines JD Jr, Gardner DM, Baldessarini RJ (1997) Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy. J Clin Psychiatry 58: 137–145

    PubMed  Google Scholar 

  • Bondolfi G, Chautems C, Rochat B (1996) Non-response to citalopram in depressive patients: pharmacokinetic and clinical consequences of a fluvoxamine augmentation. Psychopharmacology 128: 421–425

    Article  PubMed  Google Scholar 

  • Bonnet U (2003) Moclobemide: therapeutic use and clinical studies. CNS Drug Rev 9: 97–140

    PubMed  Google Scholar 

  • Carpenter LL, Josic Z, Hall JM, Rasmussen SA, Price LH (1999) Mirtazapine augmentation in the treatment of refractory depression. J Clin Psychiatry 60: 45–49

    Google Scholar 

  • Carpenter LL, Yasmin S, Price LH (2002) A double-blind, Placebo-controlled study of antidepressant augmentation with mirtazapine. Biol Psychiatry 51: 183–188

    Article  PubMed  Google Scholar 

  • Clark NA, Alexander B (2000) Increased rate of trazodone prescribing with bupropion and selective serotonin-reuptake inhibitors versus tricyclic antidepressants. Ann Pharmacother 34: 1007–1012

    Article  PubMed  Google Scholar 

  • Clayton AH, McGarvey EL, Abouesh AI, Pinkerton RC (2001) Substitution of an SSRI with bupropion sustained release following SSRI-induced sexual dysfunction. J Clin Psychiatry 62: 185–190

    PubMed  Google Scholar 

  • Dam J, Ryde L, Svejso J, Lauge N, Lauritsen B, Bech P (1998) Morning fluoxetine plus evening mianserin versus morning fluoxetine plus evening Placebo in the acute treatment of major depression. Pharmacopsychiatry 31: 48–54

    PubMed  Google Scholar 

  • Dams R, Benijts TH, Lambert WE, Van Bocxlaer JF, Van Varenbergh D, Van Peteghem C, DeLeenheer AP (2001) A fatal case of serotonin syndrome after combined moclobemide-citalopram intoxication. J Anal Toxicol 25: 147–151

    PubMed  Google Scholar 

  • DeBattista C, Solvason HB, Poirier J, Kendrick E, Schatzberg AF (2003) A prospective trial of bupropion SR augmentation of partial and no responders to serotonergic antidepressants. J Clin Psychopharmacol 23: 27–30

    Article  PubMed  Google Scholar 

  • Dimitriou EC, Dimitriou CE (1998) Buspirone augmentation of antidepressant therapy. J Clin Psychopharmacol 18: 465–469

    Article  PubMed  Google Scholar 

  • Dursun SM, Devarajan S (2001) Reboxetine plus citalopram for refractory depression not responding to venlafaxine: possible mechanisms. Psychopharmacology (Berl) 53: 497–498

    Article  Google Scholar 

  • Ebert D, Albert R, May A, Stosiek I, Kaschka W (1995) Combined SSRI-RIMA treatment in refractory depression. Safety data and efficacy. Psychopharmacology (Berl) 119: 342–344

    Google Scholar 

  • Fava M (2001) Augmentation and combination strategies in treatment-resistant depression. J Clin Psychiatry 62: 4–11

    Google Scholar 

  • Fava M, Rosenbaum JF, McGrath PJ, Stewart JW, Amsterdam JD, Quitkin FM (1994) Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression. A double-blind, controlled study. Am J Psychiatry 151: 1372–1374

    PubMed  Google Scholar 

  • Ferreri M, Lavergne F, Berlin I, Payan C, Puech AJ (2001) Benefits from mianserin augmentation of fluoxetine in patients with major depression non-responders to fluoxetine alone. Acta Psychiatr Scand 103: 66–72

    Article  PubMed  Google Scholar 

  • Fischer P, Tauscher J, Kufferle B, Kasper S (1998) Weak antidepressant response after buspirone augmentation of serotonin reuptake inhibitors in refractory severe depression. Int Clin Psychopharmacol 13: 83–86

    PubMed  Google Scholar 

  • Gomez Gomez JM, Teixido Perramon C (2000) Combined treatment with venlafaxine and tricyclic antidepressants depressed patients who had partial response to clomipramine or imipramine: initial findings. J Clin Psychiatry 61: 285–289

    PubMed  Google Scholar 

  • Hawley CJ, Quick SJ, Ratnam S (1996) Safety and tolerability of combined treatment with moclobemide and SSRI: a systematic study of 50 patients. Int Clin Psychopharmacol 11: 187–191

    PubMed  Google Scholar 

  • Hunchak J (1997) SSRI combination treatment for depression [letter]. Can J Psychiatry 42: 531–532

    PubMed  Google Scholar 

  • Joffe RT, Bakish D (1994) Combined SSRI-moclobemide treatment of psychiatric illness. J Clin Psychiatry 55: 24–25

    Google Scholar 

  • Keltner N, Harris CP (1994) Serotonin syndrome: a case of fatal SSRI/MAOI interaction. Perspect Psychiatr Care 30: 26–31

    Google Scholar 

  • Kennedy SH, McCann SM, Masellis M, McIntyre RS, Raskin J, McKay G, Baker GB (2002) Combining bupropion SR with venlafaxine, paroxetine, or fluoxetine: a preliminary report on pharmacokinetic, therapeutic, and sexual dysfunction effects. J Clin Psychiatry 63: 181–186

    PubMed  Google Scholar 

  • König F, Wolfersdorf M (1997) Combination therapy using moclobemide with tricyclic and tetracyclic antidepressants to treat therapy-resistant depression. Pharmacopsychiatry 30: 93–96

    PubMed  Google Scholar 

  • König F, Wolfersdorf M, Loble M, Wossner S, Hauger B (1997) Trimipramine and maprotiline plasma levels during combined treatment with moclobemide in therapy-resistant depression. Pharmacopsychiatry 30: 125–127

    Google Scholar 

  • Lam RW, Wan DDC, Cohen NL, Kennedy SH (2002) Combining antidepressants for treatment-resistant depression: A review. J Clin Psychiatry 63: 685–693

    PubMed  Google Scholar 

  • Landen M, Bjorling G, Agren H, Fahlen T (1998) A randomized, double-blind, Placebo-controlled trial of buspirone in combination with an SSRI in patients with treatment-refractory depression. J Clin Psychiatry 59: 664–668

    PubMed  Google Scholar 

  • Lauritzen L, Clemmensen L, Klysner R, Loldrup D, Lunde M, Schaumburg E, Waarst S, Bech P (1992) Combined treatment with imipramine and mianserine: A controlled pilot study. Pharmacopsychiatry 25: 182–186

    PubMed  Google Scholar 

  • Levitt AJ, Joffe RT, Kamil R, McIntyre R (1999) Do depressed subjects who have failed both fluoxetine and a tricyclic antidepressant respond to the combination? J Clin Psychiatry 60: 613–616

    PubMed  Google Scholar 

  • Maes M, Libbrecht I, van Hunsel F, Campens D, Meltzer HY (1999) Pindolol and mianserin augment the antidepressant activity of fluoxetine in hospitalized major depression patients, including those with treatment resistance. J Clin Psychopharmacol 19: 177–182

    Article  PubMed  Google Scholar 

  • Maes M, Vandoolaeghe E, Desnyder R (1996) Efficacy of treatment with trazodone in combination with pindolol or fluoxetine in major depression. J Affect Disord 16: 201–210

    Google Scholar 

  • Maes M, Westenberg H, Vandoolaeghe E, Demedts P, Wauters A, Neels H, Meltz HY (1997) Effects of trazodone and fluoxetine in the treatment of major depression: therapeutic, pharmacokinetic and pharmacodynamic interactions through formation of meta-chlorophenylpiperazine. J Clin Psychopharmacol 17: 358–364

    Article  PubMed  Google Scholar 

  • Nelson JC (2003) Managing treatment-resistant major depression. J Clin Psychiatry 64: 5–12

    Google Scholar 

  • Nelson JC, Mazure CM, Bowers MB, Jatlow PI (1991) A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch Gen Psychiatry 48: 303–307

    PubMed  Google Scholar 

  • Nierenberg AA, Keck PE Jr (1989) Management of monoamine oxidase inhibitor-associated insomnia with trazodone. J Clin Psychopharmacol 9: 42–45

    PubMed  Google Scholar 

  • Nierenberg AA, Cole JO, Glass L (1992) Possible trazodone potentiation of fluoxetine: a case series. J Clin Psychiatry 53: 83–85

    PubMed  Google Scholar 

  • O'Brien S, McKeon P, O'Regan M (1993) The efficacy and tolerability of combined antidepressant treatment in differend depressive subgroups. Br J Psychiatry 163: 363–368

    Google Scholar 

  • Onder E, Tural U (2003) Faster response in depressive patients treated with fluoxetine alone than in combination with buspirone. J Affect Disord 76: 223–227

    Article  PubMed  Google Scholar 

  • Razani J, White KL, White J, Simpson G, Sloane RB, Rebal R, Palmer R (1983) The safety and efficacy of combined amitiptyline and tranylcypromine antidepressant treatment. A controlled trial. Arch Gen Psychiatry 40: 657–661

    PubMed  Google Scholar 

  • Schmauss M, Kapfhammer HP, Meyr P, Hoff P (1988) Combined MAO-inhibitor and tri-(tetra)cyclic antidepressant treatment in therapy resistant depression. Prog Neuropsychopharmacol Biol Psychiatry 12: 523–532

    Article  PubMed  Google Scholar 

  • Seth R, Jennings AL, Bindman J, Philips J, Bergmann K (1992) Combination treatment with noradrenalin and serotonin reuptake inhibitors in therapy resistant depression: A retrospective study. Br J Psychiatry 161: 562–565

    PubMed  Google Scholar 

  • Tanum LH (1994) Combination treatment with antidepressant in refractory depression. Int Clin Psychopharmacology 9: 37–40

    Google Scholar 

  • Thase ME, Friedman ES, Howland RH (2000) Venlafaxine and treatment-resistant depression. Depress Anxiety 12[Suppl 1]: 55–62

    Article  PubMed  Google Scholar 

  • Weilburg JB, Rosenbaum JF, Biederman J, Sachs GS, Pollack MH, Kelly K (1989) Fluoxetine added to non-MAOI antidepressants converts nonresponders to responders: A preliminary report. J Clin Psychiatry 50: 447–449

    PubMed  Google Scholar 

  • Weilburg JB, Rosenbaum JF, Biederman J, Sachs GS, Pollack MH, Kelly K (1991) Tricyclic augmentation of fluoxetine. Ann Clin Psychiatry 3: 209–213

    Google Scholar 

  • White K, Pistole T, Boyd JL (1980) Combined monoamine oxidase inhibitor-tricyclic antidepressant treatment: a pilot study. Am J Psychiatry 137: 1422–1425

    PubMed  Google Scholar 

  • Zajecka JM, Jeffries H, Fawcett J (1995) The efficacy of fluoxetine combined with a heterocyclic antidepressant in treatment-resistant depression: A retrospective analysis. J Clin Psychiatry 56: 527–528

    Google Scholar 

  • Zimmer R, Gieschke R, Fischbach R, Gasic S (1990): Interaction studies with moclobemide. Acta Psychiatr Scand Suppl 360: 84–86

    PubMed  Google Scholar 

Download references

Authors
  1. P. Mavrogiorgou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. Juckel
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Klinik für Psychatrie und Psychotherapie, Charité — Universitätsklinik Berlin, Campus Charité Mitte (CCM), Schumannstr. 20/21, 10117, Berlin

    Michael Bauer  & Mazda Adli  & 

  2. Institut für Sozialmedizin, Epidemiologie und Gesundheitsökonomie, Charité — Universitätsklinik Berlin, Campus Charité Mitte (CCM), Luisenstr. 57, 10117, Berlin

    Anne Berghöfer

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Springer Medizin Verlag Heidelberg

About this chapter

Cite this chapter

Mavrogiorgou, P., Juckel, G. (2005). Antidepressivakombinationen. In: Bauer, M., Berghöfer, A., Adli, M. (eds) Akute und therapieresistente Depressionen. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-28049-9_17

Download citation

  • DOI: https://doi.org/10.1007/3-540-28049-9_17

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-40617-4

  • Online ISBN: 978-3-540-28049-1

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation